Biology Reference
In-Depth Information
[94] Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al.
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity
in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood
2012;119:2709-20.
[95] Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persis-
tenceofadoptivelytransferredautologousCD19-targetedTcellsinpatientswithrelapsedor
chemotherapy refractory B-cell leukemias. Blood 2011;118:4817-28.
[96] Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified
T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.
[97] Kohrt HE, Muller A, Baker J, Goldstein MJ, Newell E, Dutt S, et al. Donor immunization
with WT1 peptide augments antileukemic activity after MHC-matched bone marrow
transplantation. Blood 2011;118:5319-29.
[98] Alatrash G, Pelosini M, Saliba RM, Koca E, Rondon G, Andersson BS, et al. Platelet
recovery before allogeneic stem cell transplantation predicts posttransplantation out-
comes in patients with acute myelogenous leukemia and myelodysplastic syndrome.
Biol Blood Marrow Transplant 2011;17:1841-5.
[99] Lapenta C, Santini SM, Spada M, Donati S, Urbani F, Accapezzato D, et al. IFN-alpha-
conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells
against exogenous viral antigens. Eur J Immunol 2006;36:2046-60.
[100] Destro F, Sforza F, Sicurella M, Marescotti D, Gallerani E, Baldisserotto A, et al. Protea-
some inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen
1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells. Immunology
2011;133:105-14.
164
Search WWH ::
Custom Search